Cs4 for Pneumoconiosis Rehabilitation
Efficacy and Safety of Cordyceps Sinensis Mycelium Culture Extract (Cs4) Supplementation in Pneumoconiosis Rehabilitation: a Randomized, Controlled Trial
This clinical trial will test whether a Cordyceps supplement improves lung function. The supplement is called Cordyceps sinensis mycelium Culture extract (Cs4). The study will include adults with pneumoconiosis, a lung disease caused by breathing in mineral dust. Researchers will also assess Cs4 safety.
The main questions are: (1) does Cs4 improve lung function compared with a placebo? (2) what health problems occur while participants take Cs4?
The study will include 84 adults aged 18 to 75 years. Their breathing condition must have been stable for at least three months. The study will take place at the School of Chinese Medicine, The University of Hong Kong.
Researchers will compare Cs4 with a placebo, a look-alike capsule containing no Cs4. Chance will determine which capsules each participant receives. Each participant has an equal chance of joining either group. Participants and researchers who assess them will not know which capsules participants receive.
Participants will: (1) take two capsules of Cs4 or placebo twice daily for 24 weeks; (2) record the capsules they take each day and return unused capsules at study visits; (3) attend clinic visits for breathing tests, a walking test, and blood tests; (4)answer questions about their breathing symptoms and daily life. (5) continue follow-up visits for 12 weeks after finishing the capsules.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
- Nom: Tung Leong Fong
- Numéro de téléphone: +852 5660 4020
- E-mail: u3557512@connect.hku.hk
Sauvegarde des contacts de l'étude
- Nom: Yunqing Xun
- Numéro de téléphone: +852 5229 5427
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria: (1) adults aged 18-75 years; (2) diagnosed with pneumoconiosis based on clinical and radiological criteria, including chest X-ray/computed tomography and International Labour Organization (ILO) classification; (3)stable respiratory condition for at least 3 months before enrollment, with no acute exacerbations, hospitalizations, or changes in respiratory medication; (4)able to provide written informed consent.
Exclusion Criteria:
(1) history of chronic respiratory diseases other than pneumoconiosis that may confound FEV1/FVC assessment, such as asthma, bronchiectasis, or interstitial lung disease of other etiologies; (2) known allergy to Cordyceps sinensis or any component of the study supplement; (3) pregnancy or breastfeeding; (4)severe comorbid conditions that could interfere with participation, such as active cancer, decompensated heart failure classified as New York Heart Association (NYHA) Class III-IV, or uncontrolled psychiatric illness; (5) cognitive impairment affecting decision-making capacity.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Cs4 supplementation
Participants will receive Cordyceps sinensis mycelium culture extract (Cs4) orally at 1.6 g per day, administered as two 0.4 g capsules twice daily for 24 weeks, followed by 12 weeks of follow-up. |
Cordyceps sinensis Mycelium Culture Extract (Cs4) is a fermented mycelial preparation of Cordyceps sinensis, a fungus used in Traditional Chinese Medicine. It is produced by cultivating and fermenting the mycelium, the vegetative part of the fungus. In this trial, Cs4 is used as a dietary supplement to investigate its effects on lung function and rehabilitation outcomes in adults with pneumoconiosis. |
|
Comparateur placebo: Matching placebo
Participants will receive matching placebo orally, administered as two capsules twice daily for 24 weeks, followed by 12 weeks of follow-up. Placebo capsules will contain starch, sucrose, and food-grade colorants and will match Cs4 capsules in size, color, weight, smell, and packaging. |
Matching placebo capsules containing starch, sucrose, and food-grade colorants, with no Cs4 extract. The placebo capsules will match the Cs4 capsules in size, color, weight, and smell and will be supplied in identical blister packs to maintain blinding. Participants will take two capsules orally twice daily for 24 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Forced Expiratory Volume in One Second/ Forced Vital Capacity (FEV1/FVC) ratio
Délai: from baseline to week 24
|
Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) will be measured by trained, blinded assessors using standardized spirometry according to American Thoracic Society/European Respiratory Society standards. |
from baseline to week 24
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Forced Expiratory Volume in One Second (FEV1)
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in FEV1, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. |
Baseline, week 12, week 24, and week 36
|
|
Forced Vital Capacity (FVC)
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in FVC, measured in liters by spirometry according to American Thoracic Society/European Respiratory Society standards. |
Baseline, week 12, week 24, and week 36
|
|
Six-Minute Walk Distance (6MWD)
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in the total distance walked during the six-minute walk test, measured in meters. A longer distance indicates greater functional exercise capacity. |
Baseline, week 12, week 24, and week 36
|
|
St. George's Respiratory Questionnaire (SGRQ) Total Score
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in SGRQ total score, assessing overall impairment in respiratory health status. Scores range from 0 to 100, with higher scores indicating worse health status. |
Baseline, week 12, week 24, and week 36
|
|
Modified Medical Research Council (mMRC) Dyspnea Scale Score
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in mMRC Dyspnea Scale score, assessing limitations in daily activities caused by breathlessness. Scores range from 0 to 4, with higher scores indicating greater limitation. |
Baseline, week 12, week 24, and week 36
|
|
Leicester Cough Questionnaire (LCQ) Total Score
Délai: Baseline, week 12, week 24, and week 36
|
Change from baseline in LCQ total score, assessing cough-related quality of life using 19 items across physical, psychological, and social domains. The total score ranges from 3 to 21, with higher scores indicating better quality of life. |
Baseline, week 12, week 24, and week 36
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
High-Sensitivity C-Reactive Protein (hs-CRP) Level
Délai: Baseline, week 24, and week 36
|
Change from baseline in blood high-sensitivity C-reactive protein (hs-CRP) concentration, measured using an immunoturbidimetric assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Interleukin-6 (IL-6) Level
Délai: Baseline, week 24, and week 36
|
Change from baseline in blood IL-6 concentration, measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA). Change will be calculated separately at week 24 and week 36 by subtracting the baseline concentration from the concentration at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Malondialdehyde (MDA) Level
Délai: Baseline, week 24, and week 36
|
Change from baseline in blood MDA level, assessed using a thiobarbituric acid reactive substances (TBARS) assay. Change will be calculated separately at week 24 and week 36 by subtracting the baseline value from the value at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Superoxide Dismutase (SOD) Activity
Délai: Baseline, week 24, and week 36
|
Change from baseline in blood SOD activity, measured using a colorimetric assay based on nitroblue tetrazolium reduction. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. |
Baseline, week 24, and week 36
|
|
Glutathione Peroxidase (GPx) Activity
Délai: Baseline, week 24, and week 36
|
Change from baseline in blood GPx activity, measured using a coupled enzyme assay based on nicotinamide adenine dinucleotide phosphate (NADPH) oxidation. Change will be calculated separately at week 24 and week 36 by subtracting the baseline activity from the activity at each follow-up visit. |
Baseline, week 24, and week 36
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- UW 26-315
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
De-identified individual participant data underlying the results reported in the primary study publication will be shared, together with a data dictionary. Shared data will include participant characteristics, treatment allocation, lung function measurements, six-minute walk distance, questionnaire scores, biomarker results, and adverse event data used in the published analyses. Direct identifiers and the participant identification linkage file will not be shared. Access will be provided to qualified researchers following approval of a research proposal and execution of a data use agreement. Sharing will be subject to any required institutional review board (IRB) and institutional approvals and must be consistent with participant consent.
Délai de partage IPD
De-identified individual participant data and the selected supporting documents will be available from publication of the primary study results until five years after study completion.
Critères d'accès au partage IPD
De-identified individual participant data underlying the published results, the data dictionary, and the selected supporting documents will be available to qualified researchers upon reasonable request. Requests should be submitted by email to the principal investigator and include a methodologically sound research proposal and statistical analysis plan. The principal investigator will review requests for scientific merit, feasibility, and consistency with participant consent and institutional requirements. Approved researchers may use the data only for analyses specified in the approved proposal. Access will require a signed data use agreement and any necessary IRB and institutional approvals. Data will be provided through secure transfer.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .